REPERFUSION AND REVASCULARIZATION STRATEGIES FOR CORONARY-ARTERY DISEASE IN WOMEN

被引:36
作者
EYSMANN, SB
DOUGLAS, PS
机构
[1] BETH ISRAEL HOSP, DIV CARDIOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA
[2] HARVARD UNIV, BETH ISRAEL HOSP, THORNDIKE LAB, BOSTON, MA 02215 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1992年 / 268卷 / 14期
关键词
D O I
10.1001/jama.268.14.1903
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-One third of all deaths in women in the United States each year are attributable to coronary heart disease. Gender differences exist in the course and management of patients with coronary heart disease. Few randomized trials have been conducted in women to evaluate effective therapeutic strategies. With the aim of developing rational approaches to women with coronary heart disease, we review gender-related outcomes with coronary revascularization and reperfusion therapies. Data Source.-English-language journal articles and reviews on the subject of women with coronary heart disease or gender-specific responses to coronary heart disease management, from 1970 through 1992, identified through MEDLINE searching. Study Selection.-Selected studies included only randomized controlled trials for topics related to thrombolysis, and articles considered to contribute significantly to the topic of women with coronary artery disease in the case of angioplasty and coronary artery bypass grafting. Data Extraction.-Two reviewers participated in extracting the data with the aim of presenting a balanced and comprehensive review of the subject. Data Synthesis.-Thrombolysis in acute myocardial infarction reduces mortality in men and women, although women may have a reduced mortality benefit compared with men. Angioplasty and the newer interventional devices result in greater procedural morbidity but similar if not better long-term outcomes in women. Women may have a greater mortality rate than men with coronary artery bypass surgery, although studies suggest that outcome after bypass surgery may depend more on coronary size and preoperative risk factors than on gender itself. Conclusions.-The existence of gender differences in the course of coronary heart disease and response to revascularization and reperfusion strategies suggests the need for unique clinical approaches to the female patient with coronary heart disease and stresses the importance of developing randomized trials that enroll adequate numbers of women and that are designed to answer gender-specific questions.
引用
收藏
页码:1903 / 1907
页数:5
相关论文
共 62 条
[1]  
[Anonymous], 1987, Lancet, V2, P871
[2]  
[Anonymous], 1986, LANCET, V1, P397
[3]  
[Anonymous], 1971, Br Med J, V3, P325
[4]   RESTENOSIS AFTER TRANSLUMINAL CORONARY ANGIOPLASTY - A RISK FACTOR-ANALYSIS [J].
ARORA, RR ;
KONRAD, K ;
BADHWAR, K ;
HOLLMAN, J .
CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1990, 19 (01) :17-22
[5]   DIFFERENCES IN THE USE OF PROCEDURES BETWEEN WOMEN AND MEN HOSPITALIZED FOR CORONARY HEART-DISEASE [J].
AYANIAN, JZ ;
EPSTEIN, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (04) :221-225
[6]   CORONARY THROMBOLYSIS IN WOMEN [J].
BECKER, RC .
CARDIOLOGY, 1990, 77 :110-123
[7]   REFERRAL PATTERNS FOR CORONARY-ARTERY DISEASE TREATMENT - GENDER BIAS OR GOOD CLINICAL JUDGMENT [J].
BICKELL, NA ;
PIEPER, KS ;
LEE, KL ;
MARK, DB ;
GLOWER, DD ;
PRYOR, DB ;
CALIFF, RM .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (10) :791-797
[8]  
Bobbio M, 1991, J Invasive Cardiol, V3, P214
[9]  
BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271
[10]   HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL [J].
BOVILL, EG ;
TERRIN, ML ;
STUMP, DC ;
BERKE, AD ;
FREDERICK, M ;
COLLEN, D ;
FEIT, F ;
GORE, JM ;
HILLIS, LD ;
LAMBREW, CT ;
LEIBOFF, R ;
MANN, KG ;
MARKIS, JE ;
PRATT, CM ;
SHARKEY, SW ;
SOPKO, G ;
TRACY, RP ;
CHESEBRO, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) :256-265